Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHOA | P61586 | 1/20 | 0.37 |
| ▸ | CCR3 | P51677 | 1/20 | 0.36 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 11/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19365867 | 1.00 | RHOA (0.37) | RHOACCR3P2RY14RORCSYK | |
| SCHEMBL17624672 | 0.97 | RHOA (0.35) | RHOACCR3P2RY14RORCGSK3B | |
| SCHEMBL17618871 | 0.90 | RHOA (0.35) | RHOACCR3RORC | |
| SCHEMBL17618882 | 0.89 | RHOA (0.42) | RHOACCR3GSK3BDYRK1A | |
| SCHEMBL17624671 | 0.89 | RHOA (0.38) | RHOACCR3RORCSYKGSK3B | |
| SCHEMBL17618872 | 0.86 | RAF1 (0.35) | RHOARORC | |
| SCHEMBL16785596 | 0.86 | RHOA (0.37) | RHOACCR3RORCGSK3BDYRK1A | |
| SCHEMBL19670555 | 0.86 | RHOA (0.35) | RHOACCR3RORCGPR119IRAK1 | |
| SCHEMBL17618883 | 0.86 | RHOA (0.40) | RHOACCR3GSK3BDYRK1A | |
| SCHEMBL17618873 | 0.84 | RHOA (0.36) | RHOARORCIRAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-9834558-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-9765075-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160083386-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083386-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | RHOA 4858/4885CCR3 4873/4885P2RY14 2006/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | RHOA 4798/4885CCR3 4863/4885P2RY14 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.